SNDL Stock Gained 19.5% in November: Is it a Buy Today?

SNDL is a beaten-down Canadian cannabis producer and has trailed the market since its IPO. Is SNDL stock a buy or sell right now?

| More on:
A cannabis plant grows.

Source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Shares of SNDL (NASDAQ:SNDL) rose by almost 20% last month, valuing the Canadian cannabis company at a market cap of US$666.7 million. However, similar to other pot stocks, SNDL has also trailed the broader markets by a significant margin and is down 98% from all-time highs.

A key driver of SNDL’s stock price in November was the announcement of third-quarter (Q3) results. In the September quarter, SNDL reported revenue of $230.5 million, which was much higher than estimates of $172 million. But the company also reported a net loss of $98.8 million compared to its year-ago profit of $16.7 million.

SNDL was majorly impacted by non-cash impairments, which amounted to $86.5 million. However, its adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) stood at $18.3 million.

While the company’s recent quarterly results were cheered by investors, let’s see if SNDL stock is a top bet for long-term shareholders.

Is SNDL a good stock to buy?

SNDL recently announced the acquisition of Zenabis, a cannabis producer which filed for creditor protection. While this acquisition might not be viewed in a positive light by shareholders, it will allow SNDL to gain traction in the European Union, as Zenabis owns a GMP-certified (good manufacturing process) marijuana facility in Europe.

SNDL also disclosed plans to acquire cannabis extraction company Valens in an all-stock deal valued at $138 million. These acquisitions will make SNDL a top-10 player in the Canadian marijuana market.

SNDL ended Q3 with $325.6 million in cash, providing it with enough liquidity in the near term. It benefitted from the meme stock craze in 2021, allowing the company to raise $1 billion in cash and reduce balance sheet debt.

SNDL used the cash to acquire Alcanna, an alcohol retailer with a strong presence in Alberta. It also owns a majority stake in Nova Cannabis, the parent company of the Value Buds retail brand. Both these deals provided SNDL with a platform to expand its retail footprint and generate a positive cash flow in the future.

SNDL also formed a joint venture with SAF Group called SunStream. The joint venture provides debt to cannabis producers south of the border, enabling SNDL to enter the largest cannabis market in the world.

What’s next for SNDL stock and investors?

It’s quite possible that SNDL will continue to take advantage of a challenging macro environment and expand inorganically by purchasing potential targets at a discount. These acquisitions are expected to increase the company’s revenue from $42 million in 2021 to $719 million in 2023.

SNDL’s aggressive acquisition plans may also result in higher operating expenses. But the company reported a positive operating cash flow of $8.6 million in Q3 compared to a negative operating cash flow of $17.9 million in Q2.

While the third quarter surprised Bay Street, SNDL has to maintain its focus on improving cash flow and profit margins. Most Canadian cannabis players are grappling with oversupply and high inventory levels. This, in turn, results in significant writedowns and mounting losses.

SNDL stock is a high-risk bet, given that Canadian cannabis producers are impacted by a range of structural issues. But analysts remain bullish on SNDL stock and expect shares to rise by 45% in the next year.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool recommends Valens. The Motley Fool has a disclosure policy.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »